{
    "clinical_study": {
        "@rank": "80776", 
        "arm_group": [
            {
                "arm_group_label": "CHF6001 dry powder for inhalation  via NEXThaler\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "4 inhalations of CHF 6001 NEXThaler\u00ae"
            }, 
            {
                "arm_group_label": "CHF 6001 DPI capsules for inhalation  via Aerolizer", 
                "arm_group_type": "Active Comparator", 
                "description": "3 inhalations of CHF 6001 capsules via Aerolizer\u00ae"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the systemic availability to CHF 6001  after a\n      single dose of CHF 6001 administered using the multi-dose NEXThaler\u00ae device or the\n      single-dose capsule inhaler Aerolizer\u00ae.\n\n      CHF 6001 is an antinflammatory drug under development for Chronic obstructive pulmonary\n      disease (COPD) therapy.  The drug is presented as dry powder for inhalation delivered by an\n      inhaler device. Previous studies were conducted using a single-dose capsule inhaler\n      (Aerolizer\u00ae) device. For the subsequent clinical studies a novel multi-dose NEXThaler\u00ae\n      device will be used."
        }, 
        "brief_title": "Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler\u00ae Device or the Capsule for Oral Inhalation Via Aerolizer\u00ae Device", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "This is an Open-label, randomized, 2-way cross-over, Phase I study. The study is conducted\n      in 1 single european site. The main scope of the study is to compare the systemic\n      availability to CHF 6001 after a single dose of CHF 6001 DPI administered using the\n      multi-dose reservoir NEXThaler\u00ae device or the single-dose capsule Aerolizer\u00ae device."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject's written informed consent obtained prior to any study-related procedure\n\n          2. Able to understand the study procedures, the risks involved and ability to be trained\n             to use the devices correctly\n\n          3. Able to generate sufficient PIF\n\n          4. Male and female subjects aged 18 to 55 years inclusive\n\n          5. Body mass index (BMI) within the range of 18 to 30 kg/m2 inclusive\n\n          6. Non- or ex-smokers who smoked < 5 pack years\n\n          7. Good physical and mental status\n\n          8. Lung function within normal limits\n\n          9. Results of laboratory tests within the normal ranges\n\n         10. adequate contraception\n\n        Exclusion Criteria:\n\n          1. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before\n             inhalation of the study medication\n\n          2. Pregnant or lactating women\n\n          3. Positive HIV1 or HIV2 serology\n\n          4. Positive results from the Hepatitis serology which indicates acute or chronic\n             Hepatitis B or Hepatitis C\n\n          5. Unsuitable veins for repeated venipuncture\n\n          6. History of substance abuse or drug abuse within 12 months prior to screening visit or\n             with a positive urine drug screen\n\n          7. Subjects who have a positive urine test for cotinine at screening or at randomization\n\n          8. Clinically relevant abnormal laboratory values at screening suggesting an unknown\n             disease and requiring further clinical investigation\n\n          9. Clinically relevant and uncontrolled hepatic, gastrointestinal, endocrine, metabolic,\n             neurologic, or psychiatric disorder that may interfere with successful completion of\n             this protocol\n\n         10. Subjects who have clinically significant cardiovascular condition according to\n             investigator's judgment\n\n         11. An abnormal 12-lead ECG\n\n         12. Subjects whose electrocardiogram (12-lead ECG) shows QTcF > 450 ms for males or QTcF\n             > 470 ms for females\n\n         13. Diastolic Blood Pressure > 90 mmHg and/or Systolic Blood Pressure > 140 mmHg\n\n         14. Participation in another clinical trial where investigation drug was received less\n             than 8 weeks prior to screening\n\n         15. History of hypersensitivity to any of the excipients contained in the formulations\n             used in the trial\n\n         16. Any drug treatment, including prescribed or OTC medicines as well as vitamins,\n             homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or\n             enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital) before the screening\n             visit and likely to receive these treatments until the end of the study procedures\n             with the exception of occasional paracetamol (maximum 2 g per day with a maximum of\n             10 g per 14 days for mild non-excluding conditions), hormonal contraceptives and\n             hormonal replacement treatment for post-menopausal women\n\n         17. Treatment within the previous 3 months before the screening visit and likely to\n             receive these treatments until the end of the study procedures in the last treatment\n             period with biologic drugs and with any drug known to have a well-defined potential\n             for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole)\n\n         18. Subjects who refuse to respect the required study restrictions related to alcohol,\n             xanthine, grapefruit, food and water intake and strenuous activities\n\n         19. Heavy caffeine drinker"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119247", 
            "org_study_id": "CCD-06001AA1-07", 
            "secondary_id": "2013\u2010005490\u201041"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF6001 dry powder for inhalation  via NEXThaler\u00ae", 
                "intervention_name": "CHF 6001 dry powder for inhalation  via NEXThaler\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "CHF 6001 DPI capsules for inhalation  via Aerolizer", 
                "intervention_name": "CHF 6001 DPI capsules for inhalation  via Aerolizer", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "systemic availability , pharmacokinetics, COPD", 
        "lastchanged_date": "April 18, 2014", 
        "location": {
            "contact": {
                "email": "jos.leempoels@sgs.com", 
                "last_name": "Jos Leempoels, MD", 
                "phone": "+32 (0)3 217 25 86"
            }, 
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium", 
                    "zip": "B-2060"
                }, 
                "name": "SGS CPU Antwerpen ZNA Stuivenberg"
            }, 
            "investigator": {
                "last_name": "Joe Leempoels, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, SINGLE DOSE STUDY IN HEALTHY VOLUNTEERS TO INVESTIGATE THE PHARMACOKINETICS OF CHF 6001 DPI ADMINISTERED USING THE MULTI-DOSE RESERVOIR NEXThaler\u00ae DEVICE OR THE CAPSULE FOR ORAL INHALATION VIA AEROLIZER\u00ae DEVICE", 
        "other_outcome": [
            {
                "measure": "Vital signs: systolic blood pressure (SBP), diastolic blood pressure (DBP) and Pulse Rate (PR).", 
                "safety_issue": "Yes", 
                "time_frame": "At screening and at DAY 1 period 1 and 2"
            }, 
            {
                "measure": "Adverse events and adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "screening visit, and Day1, Day 2, Day 3, Day 4 and Day 5 for both periods 1 and 2 + FU visit/call"
            }, 
            {
                "measure": "Lung function: FEV1, to assess potential occurrence of paradoxical bronchospasm.", 
                "safety_issue": "Yes", 
                "time_frame": "at sceening and at DAY 1 Period 1 and 2"
            }
        ], 
        "overall_official": {
            "affiliation": "SGS CPU Antwerpen", 
            "last_name": "Joe Leempoels, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CHF 6001 AUC0-t (area under the plasma concentration-time curve from time 0 to the last quantifiable concentration) and Cmax (maximum plasma concentration).", 
            "measure": "Area under the plasma concentration-time curve of CHF 6001", 
            "safety_issue": "No", 
            "time_frame": "30 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours after study drug administration  at Period 1 and Period 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119247"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "CHF 6001 AUC0-2h, AUC0-96h, AUC0-\u221e, tmax (time to Cmax), t\u00bd (terminal elimination half-life ), CHF 5956 and CHF 6095 AUC0-t, Cmax, AUC0-2h, AUC0-96h, AUC0-\u221e, tmax, t\u00bd.", 
            "measure": "Other pharmacokinetic parameters for CHF 6001 and metabolites in plasma", 
            "safety_issue": "No", 
            "time_frame": "pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours after study drug administration at period 1 and 2"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}